Author:
Han Yanqi,Xu Jun,Zhu Qiang,Yang Li,Wang Yitao,Luo Hua,Zhang Tiejun
Abstract
AbstractShufeng Jiedu Capsule (SFJDC), composed of eight herbs, is a big brand traditional Chinese medicine (TCM) for the treatment of different respiratory tract infectious diseases with good clinical efficacy and few side effects. It is clinically applied to acute upper respiratory tract infection(URI), influenza, acute exacerbation of chronic obstructive pulmonary disease (AECOPD), community-acquired pneumonia(CAP) and other diseases, due to its antibacterial, antiviral, anti-inflammatory, immunoregulatory and antipyretic activities. In particular, it has shown good clinical effects for COVID-19, and was included in the fourth to tenth editions of the ‘Diagnosis and Treatment Protocol for COVID-19 (Trial)’ by the National Health Commission. In recent years, studies on the secondary development which focus on the basic and clinical application of SFJDC have been widely reported. In this paper, chemical components, pharmacodynamic material basis, mechanisms, compatibility rule and clinical application were systematically summarized, in order to provide theoretical and experimental basis for further research and clinical application of SFJDC.
Funder
National Natural Science Foundation of China
Macau Centre for Research and Development in Chinese Medicine
Research Fund of University of Macau
Macao Young Scholars Program
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine,Pharmacology
Reference73 articles.
1. Li YX. Clinical curative effect observation of Shufeng Jiedu capsule on wind-heat cold. Clin J Tradit Chin Med. 2015;27(05):674–5.
2. Hu R, Wang LH, Zhang JJ, et al. Clinical observation of Shufeng Jiedu Capsule for treating acute pharyngitis. Drug Eval Res. 2014;37(05):460–2.
3. Ren H, Jiang Y, Wang S, et al. Efficacy and safety of Shufeng Jiedu Capsule in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a protocol for systematic review and meta-analysis. Medicine. 2021;100(1): e24198.
4. Hu XY, Oliver T, Willcox M, et al. Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial. Pilot Feasibility Stud. 2022;8(1):262.
5. Zhang XW, Xia RY, Gao JQ, et al. Chinese patent medicine Shufeng Jiedu Capsules as an adjuvant therapy for community-acquired pneumonia: a systematic review and meta-Analysis of randomized clinical trials. Front Pharmacol. 2022;13: 923395.